ACADIA Pharmaceuticals Company Description
ACADIA Pharmaceuticals puts genes and drugs together to fight disease. The development-stage company uses its proprietary R-SAT technology to identify and evaluate genomic targets for drug therapies, primarily for central nervous system disorders. ACADIA hopes its lead drug candidate pimavanserin will effectively treat psychosis in patients with Parkinson's disease. In partnership with eye-care heavyweight Allergan, ACADIA is also developing therapies for glaucoma and chronic pain. Other development targets include neurological indications such as insomnia and schizophrenia.
View the Comprehensive Company Description for ACADIA Pharmaceuticals
The Company Description provides a historical perspective of ACADIA Pharmaceuticals's organization from inception to current status.
Produced by Hoover's in-house editorial team, the Company Description tracks ownership transitions, company progress via mergers and acquisitions, major growth milestones, and strategic initiatives, to provide a holistic view of ACADIA Pharmaceuticals's evolution in the marketplace.
